Clinical Indications

Globally, an estimated 30 million individuals are at risk of life-threatening invasive fungal infections. Mortality from these infections remains high – up to 80% – even with standard of care treatment.

In United States, approximately 660,000 hospitalizations with fungal infection diagnoses occur annually, with an estimated attributable cost of $6.6 billion USD. Aspergillus, Pneumocystis, and Candida infections account for 76% of fungal infection hospitalizations, and 80% of associated costs. An additional 6 million fungal diagnoses are made annually in non-hospital clinical care.*

Clinical Indications for Pan Fungal Vaccine :

· Recurrent Vulvovaginal Candidiasis [RVVC]
· Transplant (Solid Organ; Hematopoietic cell)
· Hematologic Cancers
· Pulmonary (Severe Asthma; COPD; CF)
· Autoimmunity; Inflammatory Diseases

The clinical burden of invasive fungal infections is increasing due to:

Increased prevalence of drug-resistance
treatment delays due to diagnostic challenges
suboptimal therapies
drug-drug interactions
lack of standard guidelines for prophylaxis against multiple pathogens
increase in numbers of individuals at high risk of fungal infections.

*Data source:

Healthcare Cost and Utilization Project (HCUP) National Inpatient Sample (NIS), and outpatient visit data from the National Ambulatory Medical Care Survey (NAMCS), and the National Hospital Ambulatory Medical Care Survey (NHAMCS).

[Rayens, E. and Norris, K.A.

Prevalence and Healthcare Burden of Fungal Infections in the United States, 2018. Open Forum Infect. Dis.; Infectious Disease Society of America. (2022)].

Globally, an estimated 30 million individuals are at risk of life-threatening invasive fungal infections. Mortality from these infections remains high – up to 80% – even with standard of care treatment.

Clinical Indications

Globally, an estimated 30 million individuals are at risk of life-threatening invasive fungal infections. Mortality from these infections remains high – up to 80% – even with standard of care treatment.

Globally, an estimated 30 million individuals are at risk of life-threatening invasive fungal infections. Mortality from these infections remains high – up to 80% – even with standard of care treatment.

Globally, an estimated 30 million individuals are at risk of life-threatening invasive fungal infections. Mortality from these infections remains high – up to 80% – even with standard of care treatment.

Globally, an estimated 30 million individuals are at risk of life-threatening invasive fungal infections. Mortality from these infections remains high – up to 80% – even with standard of care treatment.

Globally, an estimated 30 million individuals are at risk of life-threatening invasive fungal infections. Mortality from these infections remains high – up to 80% – even with standard of care treatment.

This website uses cookies.